Monte Rosa Therapeutics Bolsa (NASDAQ: GLUE)

Últimas noticias sobre Monte Rosa Therapeutics (NASDAQ:GLUE) Bolsa

Monte Rosa Therapeutics

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics Inc

Jefferies analyst Corey Tarlowe maintains BJ's Wholesale Club (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>) with a Buy and raises the price target from $95 to $105.

News

Price Target

Analyst Ratings

Jefferies Maintains Buy on BJ's Wholesale Club, Raises Price Target to $105

TD Cowen analyst Bryan Bergin maintains Globant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLOB#NYSE">GLOB</a>) with a Buy and raises the price target from $230 to $240.

GLOB

TD Cowen Maintains Buy on Globant, Raises Price Target to $240

Jefferies analyst Corey Tarlowe maintains Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) with a Buy and raises the price target from $90 to $100.

Jefferies Maintains Buy on Walmart, Raises Price Target to $100

WIIM

ABAT

American Battery Technology shares are trading lower. The company reported Q1 financial results.

TD Cowen analyst Doug Creutz maintains Walt Disney (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) with a Hold and raises the price target from $108 to $123.

TD Cowen Maintains Hold on Walt Disney, Raises Price Target to $123

Jefferies analyst Samad Samana maintains NICE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NICE#NASDAQ">NICE</a>) with a Buy and lowers the price target from $230 to $215.

NICE

Jefferies Maintains Buy on NICE, Lowers Price Target to $215

Goatseus Maximus (CRYPTO: GOAT) has seen impressive gains, climbing 35.3% over the past week. The rally places the AI meme coin at the forefront of the meme coin market, with traders <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41432283/move-over-dogecoin-shiba-inu-ai-meme-coin-goat-prints-over-3-million-in-profit-for-whale-t">anticipating further upside</a>. 
What Happened: The gain pushed its valuation to $1 billion placing it in the top ten of the meme coin board.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Goatseus Maximus (CRYPTO: GOAT)</td>
<td>&nbsp;$1.02</td>
<td>$1 Billion</td>
<td>&nbsp;+10.7%</td>
<td>&nbsp;+33%</td>
</tr>
<tr>
<td>Popcat (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">POPCAT</a>)</td>
<td> $1.67</td>
<td>$1.6 Billion</td>
<td>&nbsp;-5.9%</td>
<td>&nbsp;+9.9%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: With prices picking up steam, crypto trader Lucky <a href="https://x.com/LuckyXBT__/status/1857396228939518186">sees</a> GOAT price action quite similar to painful Popcat price action before its own "bull run."
Crypto trader Aylo predicts a bullish trend for the meme coin.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Clear skies ahead for <a href="https://twitter.com/search?q=%24GOAT&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$GOAT</a> Time to accelerate. <a href="https://t.co/dxX2iJi3FT">pic.twitter.com/dxX2iJi3FT</a>
&mdash; Aylo (@alpha_pls) <a href="https://twitter.com/alpha_pls/status/1857432408414364014?ref_src=twsrc%5Etfw">November 15, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Daan Crypto Trades <a href="https://x.com/DaanCrypto/status/1857424121669324907">sees</a> GOAT finally getting the breakout, saying the AI meme coin is showing resilience, with dips being quickly bought up, signaling strong support.
A breakout is <a href="https://x.com/DaanCrypto/status/1856996799669530793">anticipated</a> due to its bullish chart pattern. As a leader in the AI meme coin meta, GOAT still lacks a Binance spot listing, but such a development could further boost its momentum.
What&#8217;s Next: The influence of meme coins is expected to be thoroughly explored at Benzinga&#8217;s upcoming <a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a> event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41917072/dogecoin-is-the-best-trump-proxy-industry-expert-claims">Dogecoin Is The &#8216;Best Trump Proxy,&#8217; Industry Expert Claims</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$POPCAT

AI Meme Coin GOAT Joins $1 Billion Club—Can It Target The Likes Of Dogecoin, Shiba Inu?

<a href="https://www.theverge.com/2024/11/15/24296351/microsoft-azure-openai-adobe-meta-customers-notepad">https://www.theverge.com/2024/11/15/24296351/microsoft-azure-openai-adobe-meta-customers-notepad</a>
Microsoft has been turning its OpenAI deal into a big business. Earlier this year, much of its Azure OpenAI offering, which provides access to OpenAI's language models, was contingent on a single big spender: TikTok. But I've now seen a recent list of its top customers, and it's clear that Microsoft has managed to diversify the business with a selection of major clients spending more than $1 million per month on Azure OpenAI services.
The software giant has a running list of what it considers its top 10 customers for Azure OpenAI, and I'm told Adobe and Meta both spent more than $1 million on Microsoft's AI services in September alone to make the top 10 customer list. Both Adobe and Meta are primarily using Microsoft's provisioned output for access to OpenAI models, which provides dedicated model processing capacity rather than Microsoft's token-based offerings for text and image generation.
Meta and Adobe's use of Azure OpenAI still falls far behind TikTok owner ByteDance's, though. The Information reported earlier this year that TikTok was <a href="https://www.theverge.com/2024/7/31/24210667/microsoft-tiktok-ai-openai-customer">paying Microsoft almost $20 million</a> per month to access OpenAI's models, making up nearly a quarter of the revenue generated by Azure OpenAI at the time. ByteDance's spending on Azure OpenAI is now less than 15 percent of Microsoft's Azure OpenAI business, thanks in part to a more diverse amount of customer spending on Microsoft's AI services and ByteDance spending less.
 &nbsp;

ADBE

MSFT

Reported Earlier, 'Microsoft's Top AI Customers Include Adobe And Meta/ TikTok Is Still Microsoft's Top Azure OpenAI Customer, Though' - The Verge

TD Cowen analyst Bryan Bergin maintains Mastercard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) with a Buy and raises the price target from $533 to $567.

TD Cowen Maintains Buy on Mastercard, Raises Price Target to $567

On Friday, Vir Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIR#NASDAQ">VIR</a>) announced end-of-treatment data from Part B of the MARCH Phase 2 study evaluating combinations of tobevibart and elebsiran, with or without pegylated interferon alfa (PEG-IFNα), in participants with <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42012383/vir-biotechnology-announces-positive-end-of-treatment-results-for-tobevibart-and-elebsiran-combina" rel="noreferrer noopener">chronic hepatitis B</a>.
Chronic hepatitis B (CHB) is a long-lasting, inflammatory liver disease caused by the hepatitis B virus (HBV).
The World Health Organization estimates that 254 million people live with CHB, and an estimated 1.1 million yearly deaths are associated with the disease.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39192084/why-is-infectious-disease-focused-vir-biotechnology-stock-trading-higher-on-wednesday" rel="noreferrer noopener">Why Is Infectious Disease-Focused Vir Biotechnology Stock Trading Higher On Wednesday?</a>
Participants in the trial received tobevibart and elebsiran alone (doublet regimen) or in combination with PEG-IFNα (triplet regimen).
The study demonstrated promising rates of hepatitis B surface antigen (HBsAg) loss (seroclearance) in participants with low baseline HBsAg (&lt;1000 IU/mL) in both combination regimens.
The doublet and triplet regimens resulted in HBsAg loss at the end of treatment in 39% (7/18) and 46% (5/11) of participants with baseline HBsAg&lt;1,000 IU/mL, respectively.
The proportion of participants with varying baseline HBsAg levels who achieved HBsAg loss at the end of treatment was 16% (8/51) for the doublet and 22% (6/27) for the triplet regimen.
The doublet regimen resulted in 50% (4/8) of participants achieving HBsAg loss and anti-HBs seroconversion.
All participants with HBsAg loss at the end of treatment who received the triplet regimen achieved anti-HBs seroconversion (100%, 6/6).
Participants with HBsAg seroclearance at the end of treatment who meet eligibility criteria will discontinue treatment. A functional cure assessment will occur 24 weeks after treatment discontinuation.
Mark Eisner, Executive Vice President and Chief Medical Officer, Vir Biotechnology, said, &#8220;We are encouraged by these results and eagerly anticipate the functional cure data in 2025, as it will be decisive for the next steps of clinical development.&#8221;
Price Action: VIR stock is down 7.50% at $7.99 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42012040/bristol-myers-faces-renewed-67-billion-lawsuit-over-drug-approval-delays-amid-resolved-trustee-issue" target="_blank" rel="noreferrer noopener">Bristol-Myers Faces Renewed $6.7 Billion Lawsuit Over Drug Approval Delays Amid Resolved Trustee Issue</a></li>
</ul>

Biotech

Health Care

Movers

General

What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday?

<a href="https://www.nyserda.ny.gov/About/Newsroom/2024-Announcements/2024-11-15-NYSERDA-Issues-Advanced-Nuclear-Technologies-Request-For-Information#:~:text=Through%20this%20RFI%2C%20NYSERDA%20seeks,at%20Governor%20Kathy%20Hochul's%20direction.">https://www.nyserda.ny.gov/About/Newsroom/2024-Announcements/2024-11-15-NYSERDA-Issues-Advanced-Nuclear-Technologies-Request-For-Information#:~:text=Through%20this%20RFI%2C%20NYSERDA%20seeks,at%20Governor%20Kathy%20Hochul's%20direction.</a>
The New York State Energy Research and Development Authority (NYSERDA) today announced the issuance of a Request for Information (RFI) to gauge market interest in activities to develop advanced nuclear energy technologies in New York State. Through this RFI, NYSERDA seeks to identify entities that are currently pursuing or interested in a potential role in advanced nuclear energy development. Responses will help inform next steps following the Future Energy Economy Summit held in September at Governor Kathy Hochul's direction. Today's announcement demonstrates the State's continued commitment to remain at the forefront of emerging technologies to support the advancement of renewable energy resources and foster continued economic development.
NYSERDA President and CEO Doreen M. Harris said, "As local, national and international companies pursue nuclear energy for their on-site energy needs and the federal government signals interest in investing in this resource, we recognize that now is the time to position New York to fully engage this new sector that can drive significant economic development. Understanding the status of potential opportunities through this RFI will enable us to begin developing strategic partnerships and initiatives for complementary resources that will ultimately support the increased deployment of renewables as we work toward a zero-emission grid of the future."
Entities encouraged to respond include:
<ul>
<li>stakeholders who may be considering advanced nuclear solutions, such as users of large electric loads, industrial heat, and hydrogen – both those already active in New York and those considering establishing operations in New York;</li>
<li>supply chain companies that could provide critical components for development of advanced nuclear energy projects in New York;</li>
<li>potential host communities for nuclear reactors or supply chain projects</li>
<li>workforce development and training entities;</li>
<li>nuclear generation project developers;</li>
<li>financing/funding entities; and</li>
<li>research and development entities including laboratories, universities and private entities.</li>
</ul>
Generation project consideration associated with this RFI is restricted to New York Independent System Operator (NYSISO) Control Area Load <a href="https://www.nyiso.com/documents/20142/1397960/nyca_zonemaps.pdf/8c3807e1-5bab-ab44-3c71-2c8e61b5748b">Zones A-F <img src="https://www.nyserda.ny.gov/-/media/Project/Common/General/Rest/new-window.gif" alt="Link opens in new window - close new window to return to this page." /></a> which encompasses the area of New York State north and west of the lower Hudson Valley. All other aspects of the request including energy consumers, supply chain, and workforce apply to all parts of New York State.
Responses are preferred by December 16, 2024, to inform future engagement opportunities and planning. Responses may be submitted through NYSERDA's <a href="https://nyserda.seamlessdocs.com/f/AdvancedNuclearRFI">online portal <img src="https://www.nyserda.ny.gov/-/media/Project/Common/General/Rest/new-window.gif" alt="Link opens in new window - close new window to return to this page." /></a>. To view the RFI, visit NYSERDA's <a href="https://www.nyserda.ny.gov/Funding-Opportunities/Current-Funding-Opportunities">website</a>. Technical questions regarding this RFI may be directed to <a href="mailto:NuclearRFI@nyserda.ny.gov">NuclearRFI@nyserda.ny.gov <img src="https://www.nyserda.ny.gov/-/media/Project/Common/General/Rest/new-window.gif" alt="Link opens in new window - close new window to return to this page." /></a>.
Separate from today's announcement, later this year, NYSERDA also anticipates releasing a Final Blueprint for Consideration of Advanced Nuclear Technologies which was informed through public comments collected on the <a href="https://www.nyserda.ny.gov/summit">Draft Blueprint <img src="https://www.nyserda.ny.gov/-/media/Project/Common/General/Rest/new-window.gif" alt="Link opens in new window - close new window to return to this page." /></a> released at the Future Energy Economy Summit in September. The Summit put forward actions and needs associated with the simultaneous advancement of economic growth and a zero-emission electricity system in New York State, addressing increasing energy demands due to new economic development opportunities, acceleration of renewable energy development, as well as advancement of the technologies that will be necessary to enable a deeply renewable grid.
In addition to the RFI and the Final Blueprint for Consideration of Advanced Nuclear Energy Technologies in progress, other actions underway to inform planning for future energy needs include:
<ul>
<li><a href="https://energyplan.ny.gov/">New York's State Energy Plan <img src="https://www.nyserda.ny.gov/-/media/Project/Common/General/Rest/new-window.gif" alt="Link opens in new window - close new window to return to this page." /></a> update process, which commenced in September 2024 and will address all parts of the New York energy sector; and</li>
<li>The Public Service Commission Proceeding on Motion of the Commission to Implement a Large-Scale Renewable Program and a Clean Energy Standard ("0x40") <a href="https://documents.dps.ny.gov/public/MatterManagement/CaseMaster.aspx?Mattercaseno=15-E-0302">NYSDPS-DMM: Matter Master <img src="https://www.nyserda.ny.gov/-/media/Project/Common/General/Rest/new-window.gif" alt="Link opens in new window - close new window to return to this page." /></a>, which focuses on pursuing the target of zero emissions in the electricity sector by 2040, as set out in the Climate Leadership and Community Protection Act.</li>
</ul>
Information gathered through the request announced today is considered advisory in nature and any action by NYSERDA will be subject to all applicable laws, including procedural, regulatory, and environmental review requirements.

OKLO

"Advanced Nuclear Technologies Request For Information Announced To Gauge Market Interest; Seeks To Identify Entities Pursuing Or Interested In Potential Role In Development Of Advanced Nuclear Energy In New York" - NYSERDA

TD Cowen analyst Yaron Werber maintains Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Buy and lowers the price target from $160 to $153.

ASND

TD Cowen Maintains Buy on Ascendis Pharma, Lowers Price Target to $153

Janney Montgomery Scott analyst Timothy Coffey upgrades Hanmi Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAFC#NASDAQ">HAFC</a>) from Neutral to Buy.

Upgrades

HAFC

Janney Montgomery Scott Upgrades Hanmi Financial to Buy

<a href="https://www.wsj.com/business/media/investor-building-newspaper-chain-eyes-lee-enterprises-dallasnews-9f2c1f54">https://www.wsj.com/business/media/investor-building-newspaper-chain-eyes-lee-enterprises-dallasnews-9f2c1f54</a>
&nbsp;
A Florida billionaire with a fondness for local news is looking to build a newspaper giant by potentially scooping up publishers <a href="https://www.wsj.com/market-data/quotes/LEE">Lee Enterprises</a> and <a href="https://www.wsj.com/market-data/quotes/DALN">DallasNews</a>.
David Hoffmann, who last month disclosed a 5.2% stake in Lee Enterprises, has raised that interest to 8.7%, making him the Davenport, Iowa, company's second-largest shareholder.

DALN

'Investor Building Newspaper Chain Eyes Lee Enterprises, DallasNews; Florida Billionaire David Hoffmann Aims To Create The Second-Largest Newspaper Group In America' - WSJ

TD Cowen analyst Oliver Chen maintains Capri Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPRI#NYSE">CPRI</a>) with a Hold and lowers the price target from $57 to $22.

CPRI

TD Cowen Maintains Hold on Capri Holdings, Lowers Price Target to $22

<a href="https://newsroom.snap.com/snap-os-v558">https://newsroom.snap.com/snap-os-v558</a>
For developers, we believe that camera access unlocks the full potential of AR. Today, we're launching Snap OS v5.58, which includes new Lenses that showcase the power of the Spectacles camera and SnapML, as well as platform features and capabilities to help you better build and experiment with Spectacles Lenses.
Introducing Piano Tutor and Ball Games
&nbsp;
The Piano Tutor Lens puts a personal instructor and interactive courses at your fingertips. Powered by SnapML, the Lens uses a custom machine learning model to identify and track a variety of pianos, overlaying notes onto the keys in real-time. This helps you build awareness of the keyboard layout and coordinate your movement accordingly. Using another custom ML model, the Lens can detect how well you play and provide real-time feedback.
The Ball Game Lens is a game that transforms a physical ball into a controller, making it easy and fun to practice your skills through a set of different challenges. Using a custom ML tracking model, the Lens follows the ball's movements, allowing you to interact with physical and digital elements together and master the perfect kick.
New Platform Features and APIs
&nbsp;
To unlock the ability to experiment further in development, we're introducing new APIs that make it easy to use camera data and multi-modal Large Language Models (LLMs) hosted in the cloud. Using extended permissions developer settings and our new Fetch API, you can now build Lenses that directly interface with hosted multi-modal LLMs.
We're also introducing an Image Spatialization API, which leverages generative AI to convert common 2D image formats into 3D. Developers can now incorporate this API into their Lenses to create stunning 3D effects with such realistic depth you'll feel like you're truly in the moment.&nbsp;
Additional platform capabilities include:
Spatial Anchors: Anchor digital objects to specific locations within a Lens and return to them later
Basic Location: Get access to the GPS coordinates of your Spectacles to create more realistic outdoor experiences
Layout Mode: Import images from your phone using the Spectacles app and spatialize them for a captivating 3D experience
Web View: Drag and drop embed web pages directly into your Lenses
Lens Unlock: Unlock a Lens that has been submitted to Spectacles, but hasn't yet been added to a category or Lens Explorer, by simply sharing the URL&nbsp;
 To experience these Lenses and start building using the new features, update to the latest version of Snap OS and the Spectacles App using <a href="https://support.spectacles.com/hc/en-us/articles/30214953982740-Updating?lang=en-US">these instructions</a>. We can't wait to see what you create!

SNAP

'Snap Introducing New Lenses, Platform Features, And Capabilities For Spectacles' - Snap Newsroom

Economist and news analyst Larry Kudlow could return to a role in the White House with the former National Economic Council Director being eyed for a role among Donald Trump's growing list of possible <a href="https://www.benzinga.com/government/regulations/24/11/41993115/trump-taps-rfk-jr-for-health-secretary-role-sends-5-vaccine-stocks-lower">Cabinet nominees and advisors.</a>
What Happened: Kudlow, who is a Fox Business Network host, served as the<a href="https://www.benzinga.com/topic/larry-kudlow"> National Economic Council Director </a>for Trump from 2018 to 2021.
Kudlow is being eyed to return to the Trump administration after Trump's recent win in the<a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election"> 2024 presidential election.</a>
The economist, who met with Trump recently at Mar-a-Lago, could be considered to lead the National Economic Council once again or for a role within the Treasury Department, as <a href="https://www.wsj.com/politics/larry-kudlow-economic-role-trump-cabinet-3af2a446?mod=hp_lead_pos2">reported </a>Friday by the Wall Street Journal.
Kudlow has remained in touch with Trump since leaving the White House and has spoken positively of the president-elect on Fox Business, leading to Trump allies supporting the economist&#8217;s return to a White House role, according to the report.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent111524">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: Kudlow began his role as National Economic Council Director in April 2018 and remained in the role until the end of Trump's presidency. While other members of Trump's cabinet and administration left or got fired, Kudlow stayed. 
Reports of Kudlow being considered for a White House role comes as some Trump allies say there is a growing battle between several candidates like Howard Lutnick and Scott Bessent for economic roles in the Trump administration.
The campaigning for the role of Treasury secretary has upset Trump, according to the report, which could mean he goes a different direction in naming his new economic advisor and leadership picks.
Other names being considered for economic positions include Apollo Global Management CEO Marc Rowan and former U.S. trade representative Robert Lighthizer, the WSJ reported. 
The week has been full of several announcements from Trump on who he is planning to nominate for key White House roles once his term begins in January. More announcements are expected between now and then. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/legal/24/11/41956594/matt-gaetz-is-trumps-attorney-general-pick-would-be-top-cop-is-under-house-ethics-investigation">Matt Gaetz Is Trump&#8217;s Attorney General Pick: Would-Be Top Cop Is Under House Ethics Investigation</a></li>
</ul>
Photo via Shutterstock.

Government

Politics

Larry Kudlow As Trump Economic Advisor? Fox Business Host Under Consideration For Return To White House

TD Cowen analyst John Kernan maintains TJX Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TJX#NYSE">TJX</a>) with a Buy and raises the price target from $125 to $130.

TD Cowen Maintains Buy on TJX Companies, Raises Price Target to $130

Grown Rogue International Inc. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/GRIN#CSE">GRIN</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GRUSF#OTC">GRUSF</a>) reported its third quarter 2024 results on Thursday for the three months ended Sept. 30, 2024.
"This was another exciting quarter for Grown Rogue with solid financial metrics showing the continued execution by our team in competitive markets against a backdrop of modest price compression," CEO Obie Strickler said. "We continue to see strong indoor production yields of craft-quality flower, retail buyer and consumer loyalty, and great initial reception and sell-through with our branded pre-rolls, including our newest brand Yeti."
<h3 class="wp-block-heading">Q3 2024 Financial Highlights</h3>
The comparison period for 2023 is the three months ended Oct. 31, 2023, due to the fiscal year-end change from Oct. 31 to Dec. 31. 
<ul>
<li>Revenue totaled $7 million, up 7% compared to $6.5 million in the fourth quarter of 2023.</li>
<li>Gross profit amounted to $3.9 million, a decrease from $4.4 million in Q4 2023, primarily due to lower margins in Oregon and pricing pressures.</li>
<li>Adjusted EBITDA was positive at $2.1 million, unchanged from the previous quarter. Its margin was 30%, down 210 basis points from the fourth quarter of 2023.</li>
<li>Operating cash flow was $1.21 million, down 24% from $1.5 million in the fourth quarter of 2023. The decrease was attributed to increased spending on the New Jersey market launch.</li>
<li>Operating expenses increased by 35% to $2.95 million due to higher selling, general and administrative expenses.</li>
<li>The net loss was $667,240, an improvement from the $2.01 million recorded in the same period last year.</li>
<li>Cash and cash equivalents totaled $5.6 million, down from $6.8 million as of Dec. 31, 2023.</li>
<li>Positive cash flow of $5.01 million for the quarter.</li>
<li>Total assets grew to $41.3 million, up from $29.6 million at year-end 2023.</li>
</ul>
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/08/40576446/grown-rogue-cannabis-reports-record-q2-revenue-and-adjusted-ebitda-nj-and-illinois-major-growth-">Grown Rogue Cannabis Reports Record Q2 Revenue And Adjusted EBITDA, NJ And Illinois Major Growth Drivers</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Other Business Highlights</h3>
In New Jersey, Grown Rogue announced competition of the company's first harvest in the state, with product drops expected in Dec. 2024. The company is optimistic about generating significant cash flow from this market.
It also announced the commencement of phase I operations in the Garden State, which includes roughly 8,000 square feet of flowering canopy that will produce 500-600 pounds of whole flower per month with sales anticipated in the fourth quarter of 2024.
In Illinois, phase II construction is progressing, with a target of 1,100 pounds of whole flower production per month once completed in mid-2025.
Subsequent to quarter-end, the company announced the termination of an advisory agreement with Vireo Growth Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VREOF#OTC">VREOF</a>).
<h3 class="wp-block-heading">Outlook</h3>
Grown Rogue said it will focus on its New Jersey and Illinois expansions as primary growth drivers for 2025.
Additionally, Phase II of the New Jersey operation is expected to be completed by mid-2025, with the Illinois project following later in the year.
<h3 class="wp-block-heading">GRUSF Price Action</h3>
Grown Rogue's shares traded 2.94% higher at 7 cents per share after the market close on Thursday afternoon.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/10/41284994/grown-rogue-secures-800k-vireo-forfeits-4-5m-warrants-in-cannabis-shakeup-whats-next-for-both">Grown Rogue Secures $800K, Vireo Forfeits 4.5M Warrants In Cannabis Shakeup—What&#8217;s Next For Both?</a></li>
</ul>

Cannabis

Earnings

CSE:GRIN

Grindrod Shipping Holdings Ltd Ordinary Shares

GRIN

GRUSF

VREOF

Cannabis Co. Grown Rogue Reports 7% Increase In Q3 Revenue, Focuses On New Jersey And Illinois Expansion

TD Cowen analyst Oliver Chen maintains Sally Beauty Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBH#NYSE">SBH</a>) with a Hold and raises the price target from $13 to $14.

TD Cowen Maintains Hold on Sally Beauty Holdings, Raises Price Target to $14

The latest update is out from Monte Rosa Therapeutics ( ($GLUE) ). Monte Rosa Therapeutics has entered a global license agreement with Novartis to ...

Monte Rosa Enters Global License Agreement with Novartis

Monte Rosa jumps on $150M license deal with Novartis

Piper Sandler raised the firm's price target on Monte Rosa Therapeutics (GLUE) to $20 from $16 and keeps an Overweight rating on the shares after t...

Monte Rosa Therapeutics price target raised to $20 from $16 at Piper Sandler

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Boeing (BA) will offer 90M shares of c...

Boeing to offer 90M common shares, Philips reports mixed Q3: Morning Buzz

Monte Rosa: Novartis Deal Bolsters MGD Platform With Flush Of Cash

Analyst Derek Archila from Wells Fargo maintained a Buy rating on Monte Rosa Therapeutics (GLUE – Research Report) and keeping the price target at ...

Monte Rosa Therapeutics Gains Momentum with Strategic NVS Partnership and Positive Market Response

Monte Rosa Therapeutics GAAP EPS of -$0.29

TD Cowen analyst Marc Frahm has maintained their bullish stance on GLUE stock, giving a Buy rating on October 28. Marc Frahm has given his Buy rati...

Optimistic Outlook and Buy Rating on Monte Rosa Therapeutics Due to Promising Clinical Progress and Strategic Collaborations

Monte Rosa Therapeutics, Inc. ( ($GLUE) ) has released its Q3 earnings. Here is a breakdown of the information Monte Rosa Therapeutics, Inc. presen...

Monte Rosa Therapeutics Expands Pipeline with Novartis Deal

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on RegenXBio (RGNX – Research Report), Gossamer Bio (...

Analysts Conflicted on These Healthcare Names: RegenXBio (RGNX), Gossamer Bio (GOSS) and Monte Rosa Therapeutics (GLUE)

AAPL

ABBV

AMGN

ARLP

COIN

CORZ

CPAY

EQNR

GLUE

GOOG

GOOGL

GOSS

INTC

NPPXF

NTTYY

NVSEF

PRCT

REAL

RGNX

RHHBF

RHHBY

RHHVF

TVGN

Press Releases

Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160

Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day

Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tumors

Comments

Monte Rosa Therapeutics

Noticias

Últimas noticias sobre Monte Rosa Therapeutics (NASDAQ:GLUE) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL